Uramustine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Uramustine''', also known as ''' | {{DISPLAYTITLE:Uramustine}} | ||
== Uramustine == | |||
[[File:Uramustine.svg|thumb|right|Chemical structure of Uramustine]] | |||
'''Uramustine''', also known as '''uracil mustard''', is a chemotherapy drug that belongs to the class of [[alkylating agents]]. It is primarily used in the treatment of certain types of [[cancer]], particularly [[chronic lymphocytic leukemia]] (CLL). Uramustine is a derivative of [[uracil]], a component of [[RNA]], and it functions by interfering with the growth of cancer cells. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Uramustine works by | Uramustine works by forming cross-links between DNA strands, thereby inhibiting DNA replication and transcription. This action prevents the cancer cells from dividing and growing, ultimately leading to cell death. As an alkylating agent, uramustine is effective in both resting and rapidly dividing cells, making it a versatile option in cancer treatment. | ||
== | == Clinical Use == | ||
Uramustine is used in the | Uramustine is used in the management of chronic lymphocytic leukemia, a type of cancer that affects the [[blood]] and [[bone marrow]]. It is often administered in combination with other chemotherapy agents to enhance its efficacy. The drug is typically given intravenously, and the dosage is determined based on the patient's body surface area and overall health condition. | ||
== Side Effects == | == Side Effects == | ||
Like | Like many chemotherapy drugs, uramustine can cause a range of side effects. Common side effects include [[nausea]], [[vomiting]], [[hair loss]], and [[myelosuppression]], which is a decrease in the production of blood cells. Patients receiving uramustine are closely monitored for signs of [[infection]] and [[anemia]] due to the potential for bone marrow suppression. | ||
== | == Pharmacokinetics == | ||
Uramustine is metabolized in the liver and excreted primarily through the kidneys. The drug's half-life and clearance rate can vary depending on the patient's liver and kidney function. Adjustments in dosage may be necessary for patients with impaired organ function to prevent toxicity. | |||
== | == Related pages == | ||
* [[Chemotherapy]] | * [[Chemotherapy]] | ||
* [[Alkylating agent]] | * [[Alkylating agent]] | ||
* [[Chronic lymphocytic leukemia]] | * [[Chronic lymphocytic leukemia]] | ||
* [[Cancer treatment]] | |||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category: | [[Category:Antineoplastic drugs]] | ||
Latest revision as of 03:38, 13 February 2025
Uramustine[edit]
Uramustine, also known as uracil mustard, is a chemotherapy drug that belongs to the class of alkylating agents. It is primarily used in the treatment of certain types of cancer, particularly chronic lymphocytic leukemia (CLL). Uramustine is a derivative of uracil, a component of RNA, and it functions by interfering with the growth of cancer cells.
Mechanism of Action[edit]
Uramustine works by forming cross-links between DNA strands, thereby inhibiting DNA replication and transcription. This action prevents the cancer cells from dividing and growing, ultimately leading to cell death. As an alkylating agent, uramustine is effective in both resting and rapidly dividing cells, making it a versatile option in cancer treatment.
Clinical Use[edit]
Uramustine is used in the management of chronic lymphocytic leukemia, a type of cancer that affects the blood and bone marrow. It is often administered in combination with other chemotherapy agents to enhance its efficacy. The drug is typically given intravenously, and the dosage is determined based on the patient's body surface area and overall health condition.
Side Effects[edit]
Like many chemotherapy drugs, uramustine can cause a range of side effects. Common side effects include nausea, vomiting, hair loss, and myelosuppression, which is a decrease in the production of blood cells. Patients receiving uramustine are closely monitored for signs of infection and anemia due to the potential for bone marrow suppression.
Pharmacokinetics[edit]
Uramustine is metabolized in the liver and excreted primarily through the kidneys. The drug's half-life and clearance rate can vary depending on the patient's liver and kidney function. Adjustments in dosage may be necessary for patients with impaired organ function to prevent toxicity.
